Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Whole body MRI scans in people with certain blood and cancer conditions

Studies whole body MRI scans in adults with lymphoma, prostate, breast, or myeloma conditions.

Key facts

Who runs it
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Where
Bologna, Meldola, and Milan, ItalySee the 3 sites
Trial code
Registry title
Whole Body MRI in Oncology
Status
Recruiting
People taking part
1,000 people, planned
Started
26 Oct 2023
Expected to end
Oct 2031
Type of study
Observational, 3 groups
Treatments tested
  • Whole Body-Magnetic Resonance Imaging (WB-MRI)
Record updated
30 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have lymphoma, advanced prostate cancer, advanced breast cancer, or a multiple myeloma-related condition and who are planned for a whole-body MRI scan in routine care.

Age
18 years or older
Sex
Men and women can join
Disease stage
Lymphoma, advanced prostate cancer, advanced breast cancer, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or multiple myeloma

Main reasons for not taking part

  • Has an MRI-unsafe prosthesis or device
  • Test is of poor quality, was stopped, or is incomplete
  • Life expectancy of 3 months or less
  • Cannot or will not give informed consent

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients candidate to WB-MRI according to clinical practice belonging to the study groups listed above
  • Participant is willing and able to give informed consent for participation in the study
  • Male or Female, aged ≥ 18 years
  • Life expectancy greater than 3 months

Who cannot take part

  • Patients with MRI-unsafe prostheses and devices
  • Patients whose tests are of suboptimal quality, or whose test has been suspended, or is incomplete

Where in Italy

  • IRCCS - Azienda Ospedaliero-Universitaria di Bologna - Policlinico di S. OrsolaBologna, ItalyContact: Stefano BrocchiTaking people
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.Meldola, ItalyContact: Alice RossiTaking people
  • IRCCS Istituto Europeo di Oncologia S.r.l.Milan, ItalyContact: Giuseppe PetraliaNot yet recruiting

About the trial

What the trial wants to find out

Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study.

The 3 groups in the trial

  • Patients affected by Monoclonal plasma cell disorders

    Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Multiple Myeloma (MM).

    Treatment: Whole Body-Magnetic Resonance Imaging (WB-MRI)

  • Patients affected by advanced prostate cancer (APC) or advanced breast cancer (ABC)

    Patients affected by advanced prostate (APC) or breast cancer (ABC) with high suspicious of metastasis particularly in case of diagnostic doubt in other imaging methods (Computed tomography (CT), Positron Emission Computed Tomography (PET/CT), Bone Scintigraphy (BS)).

    Treatment: Whole Body-Magnetic Resonance Imaging (WB-MRI)

  • Patients affected by Lymphomas.

    Treatment: Whole Body-Magnetic Resonance Imaging (WB-MRI)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Whole Body MRI in Oncology
Plain-language title
Whole body MRI scans in people with certain blood and cancer conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 March 2025